Lozenges are the flavored solid, unit dosage medicated dosage forms usually in the sweetened base intended to be sucked and held in the mouth or pharynx containing one or more medicaments. Lozenges were developed in 20th century and are still under commercial production. These are medicated confections designed for local as well as systemic therapy. Carbamazepine (CBZ) is an anticonvulsant drug used in the treatment of epilepsy and neuropathic pain. It is used in schizophrenia along with other medications. In the present study an attempt has been made to prepare and evaluate the sugar based medicated Carbamazepine lozenges to improve bioavailability and increase patient compliance especially for those patients who have difficulty in swallowing. The lozenges were prepared using sucrose as base; HPMC K4M, methyl cellulose were used as polymers. Eudragit was used as taste masking agent. Formulations were prepared by heating and congealing method on laboratory scale. All the formulations prepared were subjected to various physicochemical parameters like hardness, friability, weight variation, drug content and in vitro dissolution studies. Stability studies of selected formulations of batch CL4 were also carried out at 40/75% relative humidity for 6 months for a period of six months. There wasn’t any substantial interaction between the drugs, flavor and color and other parameters and the prepared formulations were found to be stable.

**Keywords:** Carbamazepine (CBZ), in-vitro dissolution, HPMC K4M, Lozenges, stability studies, swallowing.

**INTRODUCTION**

The word "Lozenge" is derived from French word "Losenge" which indicates a diamond shaped geometry with four equal sides. Lozenges are the flavored medicated solid, unit dosage forms intended to be sucked and held in the mouth or pharynx containing one or more medicaments usually in the sweetened base. They dissolve slowly in the mouth and so release the drug dissolved in the saliva. The drugs having a large dose can be easily administered formulating as lozenges. The oral route of drug administration is most preferred route because of many advantages associated with it like ease of ingestion, pain avoidance, versatility and most important patient compliance. However geriatric and pediatric patients suffer from dysphagia (difficulty in swallowing), thus oral route for administration it has poor bioavailability of 42-58%. It’s plasma half-life is about 30 hours when it is given as single dose, but it is a strong inducer of hepatic enzymes and the plasma half-life shortens to about 15 hours when it is given repeatedly. It is highly lipophilic with an aqueous solubility of 0.078 mg/mL. After oral administration it has poor bioavailability of 42-58%. It is a bitter drug with an unpleasant aftertaste.

In present study lozenges of Carbamazepine were prepared in order to improve bioavailability and increase patient compliance.

**MATERIALS AND METHODS**

Carbamazepine was obtained from Reals Pharmaceuticals Limited, Lagos, Nigeria. Eudragit E 100, methyl cellulose, Polycethylene glycol 8000 and HPMC K4M were obtained from AC drugs ltd (Enugu, Nigeria). Sucrose and dextrose were provided by...
McNichols Plc, Ogun State, Nigeria. Citric acid was obtained from Mezk Global Limited (Lagos)

**Preparation of Carbamazepine lozenges**

Carbamazepine lozenges were prepared in laboratory scale by heating and congealing technique, the composition as given in table 1. Required quantity of all ingredients were transferred into a copper bowl, and then heated in a heating mantle at 150°C for 15 minutes. Then the temperature of the mixture was brought into 90°C, then Carbamazepine, polymers, flavoring agent and coloring agent were added with stirring by using glass rod, and the solution was transferred into a lubricated mould. It was allowed to cool for solidification then lozenges were collected and packed in an aluminum foil.

**EVALUATION OF FORMULATIONS**

1. **Measurement of thickness**

The thickness of Carbamazepine lozenges were determined using Vernier callipers. Three lozenges from each batch were used and average values were calculated.

2. **Weight variation**

The formulated Carbamazepine lozenges were tested for weight uniformity. Twenty formulations were collectively and individually weighed. From the collective weight, average weight was calculated. Each lozenge weight was then compared with average weight to ascertain whether it is within permissible limits or not.

3. **Hardness**

The lozenge crushing strength, which is the force required to break the lozenge by compression in the diametric direction. The hardness of the Carbamazepine lozenges was determined by using Monsanto Hardness tester, where the force required to break the lozenges was noted. It is expressed in kg/cm². Ten formulations of each batch were used for the estimation of hardness.

4. **Friability**

The Roche friability test apparatus was used to determine the friability of the lozenges. Six pre weighed Carbamazepine lozenges were placed in the apparatus, for 4 min at 25 rpm. Then the lozenges were reweighed. The percentage friability was calculated by using the formula.

\[
\text{% Friability} = \frac{\text{Initial weight} - \text{Final weight}}{\text{Initial weight}} \times 100
\]

5. **Drug content**

Three Carbamazepine lozenges from each batch were selected and weighed individually and crushed in a mortar. Drug was extracted with 100 ml of distilled water. The drug content was determined spectrophotometrically at 285 nm with blank lozenge extract as the reference. The formulated lozenges were evaluated for the following parameters.

6. **In vitro dissolution studies**

In vitro dissolution studies of Carbamazepine lozenges were carried out in 900 ml phosphate buffer pH 6.8 using USP dissolution testing apparatus with a rotating stirrer speed at 100 rpm, and temperature of dissolution medium maintained at 37±0.5°C. The rpm of the paddle was fixed at 100. Aliquots of 5ml were withdrawn at regular intervals; filtered and same amount of fresh dissolution medium was replaced at the same temperature. The filtered solutions were analyzed by using a spectrophotometer at 285 nm.

7. **Disintegration test**

The disintegration time of Carbamazepine lozenges were determined by USP Disintegration apparatus and disintegration time was noted in buffer of pH 6.4 at 37°C.

8. **Stability test**

For accelerated stability study, selected formulation was kept in airtight dark container according to ICH guidelines at 40/75% relative humidity for 6 months.

**RESULTS AND DISCUSSION**

Four different formulations of Carbamazepine lozenges were prepared successfully in laboratory scale by heating and congealing technique. Different ingredients i.e. Eudragit E 100, HPMC K4M, sucrose, dextrose, polyethylene glycol 8000, methylcellulose, citric acid, aspartame, talc, coloring agent, menthol were incorporated in different ratio. In the Carbamazepine lozenges formulations menthol was used as flavoring agent, it provides a desirable soothing effect. All the formulations showed good physical appearance. The prepared Carbamazepine hard lozenges evaluated for physicochemical parameters like hardness, friability, content uniformity, weight variation, thickness and drug content, results reported in the Table 3. The Thickness of the formulations was in the range of 14.23±0.12 to 14.50±0.06 cm which indicates uniformity for all formulations.

Weight variation was found to be in the range of 2.34±0.12 to 4.51±0.08%. Hardness of the formulations was in the range of 15.95±0.13 to 16.47±0.08 kg/cm². Friability was in between 0.93±0.13 and 0.96±0.07%. The results of hardness and friability indicated that the Carbamazepine lozenges formulations were mechanically stable. Drug content was found to be in the range of 95.28±0.12 to 99.82±0.52%.

Disintegration time of all Carbamazepine lozenges formulations lies in between 20±0.3 to 25±0.2 min. Thus, it can be concluded that all the formulations passed physicochemical evaluation. In-vitro release study was performed for 30 minutes, results are shown in figure 1. The percent drug release was found in the range of 55.49 to 93.27%. Carbamazepine lozenges formulations of batch CL4 showed a release of 93.27% in 30 minutes, which was relatively faster in comparison to the other formulations prepared from ordered mixture, which may be due to the presence of Polyethylene glycol 8000, which aid in faster disintegration of the prepared lozenges. Since methylcellulose is a hydrophilic polymer, it facilitates quick release of drug. But as the concentration crosses the optimum quantity it retards drug release. During stability study of 6 months of selected Carbamazepine lozenges formulations of batch CL4, it was observed that the concentrations of drug in all the formulations were decreased a bit, within the pharmacopoeia limits.
It was found that there was a slight change in taste and color of all the lozenges. Hence in the stability studies carried for six months it was found that there wasn’t any substantial changes in hardness, friability, weight uniformity, % drug content, disintegration time the selected formulations were stable throughout the study.

**CONCLUSION**

Lozenges enjoy an important position in pharmacy and will continue to remain at the same in future. From present study it is concluded that incorporating polymers like HPMC K4M and methylcellulose can be used to formulate effective medicated Carbamazepine lozenges especially for patients who cannot swallow solid oral dosage forms like tablet and capsules. This will offer better patient compliance and innovative dosage form. Lozenges are intended to slowly dissolve in the mouth over a relatively long period of time usually about 2-15 min or more as needed. By incorporation of synthetic polymers yields good results and release the drugs for a prolonged period of 30 min. Based on different parameters Carbamazepine lozenges formulations of batch CL4 can be considered as the optimized formulation.

**CONFLICT OF INTERESTS**

There are no conflicts of interest.

**REFERENCES**


<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Batch Code</th>
<th>CL1</th>
<th>CL2</th>
<th>CL3</th>
<th>CL4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Eudragit E 100</td>
<td>10</td>
<td>15</td>
<td>20</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>HPMC K4M</td>
<td>25</td>
<td>20</td>
<td>15</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Sucrose</td>
<td>800</td>
<td>740</td>
<td>730</td>
<td>700</td>
<td></td>
</tr>
<tr>
<td>Dextrose</td>
<td>-</td>
<td>-</td>
<td>30</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Polyethylene glycol 8000</td>
<td>200</td>
<td>250</td>
<td>300</td>
<td>350</td>
<td></td>
</tr>
<tr>
<td>Methylcellulose</td>
<td>25</td>
<td>20</td>
<td>15</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Citric acid</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td>30</td>
<td></td>
</tr>
<tr>
<td>Aspartame</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Talc</td>
<td>0.0126</td>
<td>0.0126</td>
<td>0.012</td>
<td>0.0126</td>
<td></td>
</tr>
<tr>
<td>Coloring agent</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td></td>
</tr>
<tr>
<td>Menthol</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td></td>
</tr>
</tbody>
</table>

**Coding Information**

CODEN (USA): UJPRA3

ISSN: 2456-8058
Table 1: Evaluation parameters for Carbamazepine lozenges formulations

<table>
<thead>
<tr>
<th>Batch code</th>
<th>Thickness (cm)</th>
<th>Hardness (Kg/cm²)</th>
<th>% Weight variation</th>
<th>% Friability</th>
<th>% Drug content</th>
<th>Disintegration time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CL1</td>
<td>14.32±0.08</td>
<td>15.95±0.13</td>
<td>3.25±0.14</td>
<td>0.96±0.07</td>
<td>96.72±0.09</td>
<td>25±0.2</td>
</tr>
<tr>
<td>CL2</td>
<td>14.50±0.06</td>
<td>16.43±0.18</td>
<td>2.42±0.07</td>
<td>0.93±0.13</td>
<td>95.28±0.12</td>
<td>24±0.1</td>
</tr>
<tr>
<td>CL3</td>
<td>14.38±0.16</td>
<td>16.35±0.08</td>
<td>4.51±0.08</td>
<td>0.94±0.25</td>
<td>97.47±0.43</td>
<td>21±0.2</td>
</tr>
<tr>
<td>CL4</td>
<td>14.23±0.12</td>
<td>16.47±0.08</td>
<td>2.34±0.12</td>
<td>0.95±0.18</td>
<td>99.82±0.52</td>
<td>20±0.3</td>
</tr>
</tbody>
</table>

Table 3: Stability study of Carbamazepine lozenges of batch CL4

<table>
<thead>
<tr>
<th>Time (Month)</th>
<th>Hardness</th>
<th>Friability</th>
<th>Weight Uniformity</th>
<th>%Drug content</th>
<th>Disintegration time (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>16.47±0.08</td>
<td>0.95±0.18</td>
<td>2.34±0.12</td>
<td>99.82±0.52</td>
<td>20±0.3</td>
</tr>
<tr>
<td>2</td>
<td>16.42±0.06</td>
<td>0.94±0.07</td>
<td>2.31±0.23</td>
<td>99.81±0.03</td>
<td>19.2±0.05</td>
</tr>
<tr>
<td>4</td>
<td>16.39±0.11</td>
<td>0.94±0.06</td>
<td>2.30±0.05</td>
<td>99.80±0.02</td>
<td>19±0.04</td>
</tr>
<tr>
<td>6</td>
<td>16.31±0.23</td>
<td>0.93±0.15</td>
<td>2.29±0.09</td>
<td>99.79±0.01</td>
<td>18.95±0.03</td>
</tr>
</tbody>
</table>

Figure 1: Physical appearance of prepared Carbamazepine lozenges

Figure 2: In-vitro drug release profile of Carbamazepine lozenges formulations

How to cite this article-